AOD-9604 is a modified C-terminal fragment of human growth hormone that preserves the lipolytic (fat-reducing) domain while lacking growth-promoting effects. It targets adipose tissue to stimulate the breakdown of stored fat and inhibit new fat storage (re-esterification) within adipocytes. At the molecular level, sustained AOD-9604 administration increases expression of β3-adrenergic receptors in fat tissue, counteracting the obesity-associated downregulation of these fat-burning receptors. In contrast to full-length hGH, AOD-9604 does not meaningfully increase IGF-1 levels or impair glucose tolerance, resulting in a tolerability profile comparable to placebo in human studies.
AOD-9604 (5mg Vial) Dosage Protocol
AOD-9604 (5mg Vial) Dosage Protocol
Quickstart Highlights
AOD-9604 dosing protocols utilize this synthetic 16-amino-acid fragment (Tyr-hGH 177–191) that has been studied for its ability to promote lipolysis (fat breakdown) and suppress lipogenesis (fat storage) without increasing IGF-1 levels or inducing insulin resistance. Clinical studies indicate that AOD-9604 demonstrates a safety profile comparable to placebo in obese adults, supporting its characterization as a well-tolerated option for metabolic support. This educational protocol describes a once-daily subcutaneous administration strategy using a practical dilution to allow accurate insulin-syringe measurements.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.667 mg/mL (1667 mcg/mL) concentration.
- Typical daily range: 300–500 mcg once daily (gradual titration).
- Easy measuring: At 1.667 mg/mL, 1 unit = 0.01 mL ≈ 16.67 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~1.667 mg/mL)
| WEEK | Daily Dose (MCG) | UNITS (PER INJECTION) (ML) |
|---|---|---|
| Weeks 1–4 | 300 mcg | 18 units (0.18 mL) |
| Weeks 5–12 | 500 mcg | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously (typically in the morning on an empty stomach). This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units ≥10 for better accuracy. Rotate injection sites (abdomen, thighs, upper arms) to minimize local irritation.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Supplies Needed
Plan based on an 8–12 week daily protocol with gradual titration (300 mcg Weeks 1–4, 500 mcg Weeks 5+).
- Peptide Vials (AOD-9604, 5 mg each):
- 8 weeks ≈ 5 vials
- 12 weeks ≈ 8 vials
- 16 weeks ≈ 11 vials
- Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 12 weeks (8 vials): 24 mL → 3 × 10 mL bottles
- 16 weeks (11 vials): 33 mL → 4 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Protocol Overview
Concise summary of the once‑daily regimen.
- Goal: Support reduction of fat mass and enhance fat oxidation over time.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 300–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 5 mg vial (~1.667 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Dosing Protocol
Suggested daily titration approach.
-
- Start: 300 mcg daily for Weeks 1–4; increase to 500 mcg for Weeks 5–12 as tolerated.
- Target: 500 mcg daily by Week 5 and maintain through cycle completion.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Morning administration (fasted) is common; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ year.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes (U‑100, 29–31 gauge); dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Each 5 mg vial provides approximately 10 days of dosing at 500 mcg/day or 16–17 days at 300 mcg/day.
How This Works
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- Supports reductions in fat mass and gradual increases in fat oxidation; clinical trials reported modest but statistically significant weight loss (approximately 2.6 kg versus 0.8 kg with placebo over 12 weeks at 1 mg/day).
- Preferential reduction of abdominal fat has been observed, resembling patterns noted with low-dose hGH therapy.
- Does not meaningfully elevate IGF-1 and demonstrates a placebo-like safety profile in human studies; no anti-AOD9604 antibodies were detected.
- Emerging regenerative potential: preclinical research suggests possible benefits for cartilage repair and bone health.
- Generally well tolerated; occasional mild injection-site reactions (redness or itching) may occur with subcutaneous administration.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a hypocaloric, protein-forward diet matched to individual energy needs; AOD-9604 should be considered a supportive aid to fat loss rather than a stand-alone solution.
- Integrate resistance training with aerobic exercise to reinforce beneficial metabolic adaptations.
- Emphasize adequate sleep and effective stress management to support adherence and recovery.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 90° (or 45° if very little subcutaneous fat) into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy.
Recommended Source
We recommend Ion Peptide for high-purity AOD-9604 (5 mg).
Why Ion Peptide?
- High-purity, third-party-tested lots with batch COAs.
- Consistent, ISO-aligned handling and documentation.
- Reliable fulfillment to help maintain cold-chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.